Zofran MDL Judge Denies Dismissal For Lack Of ‘Clear Evidence’ Of FDA Action
(Zofran opinion available. Document #28-160204-003B.)
Zofran is approved to treat post-anesthesia nausea and nausea and vomiting cause by radiation and chemotherapy. Plaintiffs allege that GlaxoSmithKline (GSK) marketed Zofran off-label for treatment of morning sickness and that the prescription drug resulted in birth defects.
GSK moved to dismiss, arguing...
To view the full article, register now.